share_log

Ladenburg Thalmann Initiates Coverage On Marker Therapeutics With Buy Rating, Announces Price Target of $11

Benzinga ·  Apr 30 10:03

Ladenburg Thalmann analyst Aydin Huseynov initiates coverage on Marker Therapeutics (NASDAQ:MRKR) with a Buy rating and announces Price Target of $11.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment